Importantly, these antagonistic TNFR2 antibodies depleted Tregs isolated from ovarian cancer ascites more potently than Tregs from healthy donor samples, implying increased tumor specificity (Torrey et al., 2017). Here, TNFRSF1B is linked to neoplasm.